In Brief: Glaxo Wellcome
This article was originally published in The Tan Sheet
Executive Summary
Glaxo Wellcome: Low-dose Zantac (ranitidine hydrochloride) in 75 mg tablets is recommended for OTC regulatory approval in Austria, Belgium, France, Germany, Italy and Luxembourg under the EU's new centralized mutual recognition procedure. The Netherlands, which approved the product in December 1995, served as the reference member state. Zantac 75 was launched in the U.K. in January 1995 and the U.S. in April 1996. Warner-Lambert will handle marketing of the product in most countries under the two companies' joint venture agreement ("The Tan Sheet" July 8, In Brief)...